INTERVIEW: ViroMed Seeks Partnerships With Active Role
This article was originally published in PharmAsia News
Executive Summary
South Korea’s ViroMed, a front runner in gene therapy involving naked plasmid DNA, is searching for global partners for its leading project VM202 but is apparently in no hurry to make a decision. In an exclusive interview, its founder and chief science officer tells PharmAsia News what sort of partnerships it is seeking and the goals it hopes to achieve in the coming years.
You may also be interested in...
ViroMed Steps Up Global Ambitions With New Gene Therapy Pipeline
ViroMed, which is conducting late phase clinical trials of its gene therapy, VM202, in the US, hopes to emerge as a top global DNA-based gene therapy company. It has a promising pipeline of CAR-T and DNA therapies and has hired a team of global experts to propel its efforts.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.